middle.news
FDA Clears Neurizon’s NUZ-001 for Pivotal ALS Platform Trial Entry
8:35am on Thursday 11th of December, 2025 AEDT
•
Biotechnology
Read Story
FDA Clears Neurizon’s NUZ-001 for Pivotal ALS Platform Trial Entry
8:35am on Thursday 11th of December, 2025 AEDT
Key Points
FDA approval granted for NUZ-001 regimen in HEALEY ALS Platform Trial
NUZ-001 designated as Regimen I in the adaptive multi-drug trial
Clinical site activations and IRB approvals underway ahead of 2026 enrollment
Trial aims to accelerate development of new ALS therapies
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neurizon Therapeutics (ASX:NUZ)
OPEN ARTICLE